Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations
Open Access
Abstract
Background: Although management guidelines exist for several genes associated with a 2‐fold to 5‐fold increase in the relative risk for certain cancers, the value of testing for them remains controversial.Methods: De‐identified personal and family history data for 654 individuals with pathogenic variants (PVs) in PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and/or RAD51D were analyzed for pretest and post‐test candidacy for guideline‐recommended management of cancer risk. These individuals were invited to complete a survey about provider recommendations and their adherence.Results: Twenty‐four percent of CHEK2, ATM, PALB2, or NBN PV carriers were appropriate for consideration of annual breast magnetic resonance imaging screening before genetic testing, with the remaining 76% appropriate only after testing. No BRIP1, RAD51C, or RAD51D PV carriers were appropriate for consideration of risk‐reducing salpingo‐oophorectomy before genetic testing; 100% were appropriate only after testing. Seventeen percent of CHEK2 PV carriers were appropriate for earlier and more frequent colonoscopy before genetic testing, with the remaining 83% appropriate only after testing. Provider recommendations for annual breast magnetic resonance imaging, consideration of risk‐reducing salpingo‐oophorectomy, and earlier and more frequent colonoscopy were reported by 42%, 26%, and 66% of breast, ovarian, and colorectal cancer risk PV carriers, respectively, before genetic testing, versus 82%, 79%, and 81%, respectively, after testing. Nearly all respondents had planned or undertaken provider‐recommended management.Conclusions: Testing for PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D changed management for those carrying PVs. Provider recommendations were aligned with guidelines, and patients adhered to recommendations, both of which are critical for reducing both long‐term cancer morbidity and mortality.Keywords
This publication has 21 references indexed in Scilit:
- Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2018
- Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findingsJournal of Cancer Research and Clinical Oncology, 2018
- Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast CancerJAMA Oncology, 2018
- Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal CancerAmerican Journal of Gastroenterology, 2017
- Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic TestingJournal of the American College of Radiology, 2017
- Counselling framework for moderate-penetrance cancer-susceptibility mutationsNature Reviews Clinical Oncology, 2016
- Gene Panel Testing for Inherited Cancer RiskJournal of the National Comprehensive Cancer Network, 2014
- Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?Journal of Clinical Oncology, 2013
- Significant differences among physician specialties in management recommendations of BRCA1 mutation carriersBreast Cancer Research and Treatment, 2011
- Cancer Surveillance Behaviors in Women Presenting for Clinical BRCA Genetic Susceptibility TestingOncology Nursing Forum, 2009